Phio completes first commercial-scale cGMP batch of PH-762; Phase 2b trial set for Q1 2027

Phio Pharmaceuticals Corp.

PH-762 drug substance (API) batch released meeting established specs, confirmed by Certificate of Analysis and Certificate of Compliance.
Manufactured under cGMP, the approved Master Batch Record and ICH Q7 guidelines, per the October 13, 2026 press release.
Validated material moves to final drug product completion for Phio's planned Phase 2b clinical study, expected to begin Q1 2027.
CEO Robert Bitterman said the milestone culminates a complex 16-month cross-functional effort and mitigates key development and manufacturing risks.
Phio is a clinical-stage biotech developing cancer therapeutics on its INTASYL siRNA gene-silencing platform; PH-762 is the lead program.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.